Electroporation News and Research

RSS

Is green leaf biomass a viable and sustainable source of protein?

In a recent study published in the journal Nutrients, researchers at North Carolina State University reviewed studies on underutilized sources of plant proteins and discussed strategies to enhance yields, extract nutrients and influence the demand and acceptance of new protein sources, especially green leaf biomass.

14 Mar 2023

mRNA vaccine methodologies: Production, value and spectrometer use

To be decided by the editor

From Thermo Fisher Scientific – Materials & Structural Analysis 16 Dec 2022

Exploring synthetic engineering of bacteriophages

In a new study, researchers demonstrated biological bacteriophage containment and synthetic engineering.

24 Nov 2022

Novel linear DNA SARS-CoV-2 vaccine using electroporation-aided vaccine delivery reveals lower viral shedding in ferrets

Researchers evaluated the efficacy, immunogenicity, and safety of a novel SARS-CoV-2 linear deoxyribonucleic acid vaccine in ferret models delivered using intramuscular injection and electroporation.

3 Oct 2022

Needle-free jet injection of novel COVID-19 DNA vaccine shows promise in animal model

In a recent study posted to the bioRxiv* server, researchers at the United States Army Medical Research Institute of Infectious Diseases evaluated the immunogenicity of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) deoxyribonucleic acid (DNA) vaccine, nCOV-S(JET), in rhesus macaques

18 Sep 2022

MaxCyte signs strategic platform license with LG Chem to advance its allogeneic CAR-T programs

MaxCyte, Inc., a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announces the signing of a strategic platform license (SPL) with LG Chem Ltd., a globally diversified chemical company established in petrochemical, advanced materials and bio-technology, aiming to create new value for its customers based on science.

From MaxCyte, Inc. 13 Jul 2022

The potential of DNA-based SARS-CoV-2 vaccine candidates

Researchers evaluated the immunogenicity of DNA-based candidate vaccines against SARS-CoV-2 in mice.

28 Jun 2022

Recent advances in non-viral nano-vector delivery of CRISPR/Cas9 genome editing payloads

Researchers reviewed non-viral nano-vectors used for delivering the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9-mediated genome editing system.

14 Apr 2022

Using mRNA to introduce gene editor into human muscle stem cells

Mutations that lead to muscle atrophy can be repaired with the gene editor CRISPR-Cas9. A team led by ECRC researcher Helena Escobar has now introduced the tool into human muscle stem cells for the first time using mRNA, thus discovering a method suitable for therapeutic applications.

14 Mar 2022

Bioactive small molecules enhance CRISPR/Cas9 loss-of-function editing in human cells

Researchers demonstrate enhanced loss-of-function editing of CRISPR/Cas9 in human cells.

14 Mar 2022

New multiple-shot electroporation device could enable low-cost, effective cancer drug delivery

Researchers from the Singapore University of Technology and Design (SUTD) have developed a microsize-gap multiple-shot electroporation (M2E) device that could improve the effectiveness of delivering cancer drugs at a lower cost, globally.

12 Feb 2022

Study shows efficacy of a heterologous vaccine regimen to induce mucosal protection against COVID-19

Researchers emphasize that an effective vaccine should induce mucosal immunity and prevent the nasal entry of SARS-CoV-2.

27 Oct 2021

New method for safe engineering of therapeutic cells with photothermal nanofibers

Professor Braeckmans from Ghent University focused the last ten years on a method for safe engineering of therapeutic cells with photothermal nanofibers.

22 Oct 2021

Innovative method greatly simplifies the complexity of delivering vaccines

Future vaccine delivery may rely on everyday items like BBQ lighters and microneedles, thanks to the ingenuity of a team of Georgia Institute of Technology and Emory University researchers.

21 Oct 2021

Phase 1 open-label trial shows SARS-CoV-2 DNA vaccine induces durable immune response

The efficacy and safety of a DNA-based vaccine are investigated, finding that the unique vaccine imparts a robust and long-lasting immunogenic response.

15 Oct 2021

Evaluation of a synthetic DNA SARS-CoV-2 vaccine INO-4800 using a nonhuman primate model

A new study published in Vaccine assesses the safety and efficacy of the synthetic DNA vaccine candidate INO-4800, delivered as a single or double dose regime.

18 Jul 2021

Researchers discover new genetic driver of autism and other developmental disorders

A research group including Kobe University's Professor TAKUMI Toru (also a Senior Visiting Scientist at RIKEN Center for Biosystems Dynamics Research) and Assistant Professor TAMADA Kota, both of the Physiology Division in the Graduate School of Medicine, has revealed a causal gene (Necdin, NDN) in autism model mice that have the chromosomal abnormality called copy number variation.

9 Jul 2021

COVID-e-Vax DNA vaccine candidate elicits robust immune responses in preclinical trials

A new study, released as a preprint on the bioRxiv* server, describes the late-stage clinical trial efficacy of a new vaccine candidate based on a deoxyribonucleic acid (DNA) plasmid platform expressing the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. Among different constructs of the vaccine plasmid, the RBD was found to produce the most potent and broad immune response.

16 Jun 2021

New DNA COVID-19 vaccine proven effective in mice

A new study has shown that a new DNA-based COVID-19 vaccine successfully induced immunization against SARS-CoV-2 in mice and hamsters.

27 May 2021

Study attempts to standardize humoral immune Correlates of Protection (CoP) in COVID-19

A new study aims to identify antibody-based biomarkers associated with the humoral immune response that could be a standard CoP candidate for COVID-19. Further, standardization of research methods to measure these biomarkers has also been conducted.

25 May 2021